Emerging prodrug and nano-drug delivery strategies for the detection and elimination of senescent tumor cells

Biomaterials, Год журнала: 2025, Номер unknown, С. 123129 - 123129

Опубликована: Янв. 1, 2025

Язык: Английский

---

LRG1-Targeted Nintedanib Delivery for Enhanced Renal Fibrosis Mitigation

Nano Letters, Год журнала: 2024, Номер 24(35), С. 11097 - 11107

Опубликована: Авг. 26, 2024

Renal fibrosis lacks effective nephroprotective drugs in clinical settings due to poor accumulation of therapeutic agents damaged kidneys, underscoring the urgent need for advanced renal-targeted delivery systems. Herein, we exploited significantly increased expression leucine-rich α-2 glycoprotein 1 (LRG1) protein during renal develop a novel drug system. Our engineered nanocarrier, DEN

Язык: Английский

---

Leucine-rich alpha-2-glycoprotein 1 deficiency suppresses ischemia–reperfusion injury-induced renal fibrosis

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Янв. 8, 2025

Ischemia reperfusion injury (IRI) is a major cause of acute kidney (AKI) and ultimately leads to renal fibrosis, primarily via the transforming growth factor-β (TGF-β) pathway. Leucine-rich alpha-2-glycoprotein 1 (LRG1), novel modulator TGF-β pathway, has been implicated in modulation fibrosis by affecting TGF-β/Smad3 signaling axis. However, role LRG1 transition from AKI chronic disease (CKD) remains unclear. This study aimed investigate functional during remodeling phase post-IRI. Unilateral IRI was induced C57BL/6J wild-type (WT) mice systemic knockout (KO) mice. In WT mice, mRNA expression significantly elevated on ischemia/reperfusion side compared sham over 28-day period. contrast, KO demonstrated reduced postoperative day 28. Additionally, associated pro-fibrotic genes diminished Consequently, exhibited attenuated IRI-induced fibrosis. These findings indicate that involved pathogenesis CKD may be potential therapeutic target.

Язык: Английский

---

LRG1-Targeted Camptothecin Nanomicelles with Simultaneous Delivery of Olaparib for Enhanced Colorectal Cancer Chemotherapy

Nano Letters, Год журнала: 2025, Номер unknown

Опубликована: Фев. 13, 2025

Camptothecin (CPT), an effective topoisomerase I inhibitor used in colorectal cancer chemotherapy, often faces limitations due to severe toxicities. Addressing this, we developed OCENM, a nanomedicine featuring the CPT–ET conjugate─comprising cathepsin B-sensitive linker and CPT linked ET peptide targeting leucine-rich alpha-2-glycoprotein 1 (LRG1) encapsulating Olaparib, potent poly ADP-ribose polymerase (PARP) inhibitor. OCENM aims for precise delivery sites overexpressing LRG1, while Olaparib disrupts compromised DNA repair pathways, enhancing damage promoting increased tumor cell apoptosis. Our results show accumulates preferentially models through LRG1 triggers synergistic apoptosis dual action of enhanced inhibited mechanisms. This study not only highlights potential as strategic target but also underscores therapeutic promise combining with treatment.

Язык: Английский

---

PROTAC based targeted degradation of LRG1 for mitigating corneal neovascularization

Journal of Controlled Release, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

---

Revealing the multiple faces of LRG1: gene expression, structure, function, and therapeutic potential

Journal of Advanced Research, Год журнала: 2025, Номер unknown

Опубликована: Май 1, 2025

Язык: Английский

---

Lenalidomide attenuates cardiac fibrosis and inflammation induced by β-adrenergic receptor activation

International Immunopharmacology, Год журнала: 2025, Номер 158, С. 114848 - 114848

Опубликована: Май 17, 2025

Язык: Английский

---